Proteologics is a biopharmaceutical company exploiting the UBIQUITIN system for the discovery and development of novel therapeutics. Drs. Avram Hershko and Aaron Ciechanover, - 2004 Nobel Prize in Chemistry laureates for the discovery of the ubiquitin system - lead our distinguished scientific advisory board. Proteologics world-class knowledge, supported by a unique target and drug discovery platform, is being used to unveil the role of ubiquitin in pathologies with the goal of developing ubiquitin system targeted drugs.

Proteologics focuses primarily on discovering inhibitors for specific E3 ubiquitin ligases (E3). These enzymes, control the conjugation of ubiquitin to target proteins, regulating protein breakdown and a variety of cellular processes. E3's are believed to offer novel drug targets for many types of cancer, metabolic disease, viral infections and CNS related disorders. On September 2008 Proteologics and Teva Pharmaceutical Industries Ltd (Teva) signed a license agreement. Under the terms of the agreement Teva received a license to further develop and commercialize lead molecules that are generated from three drug discovery programs that are currently still being developed by Proteologics for Teva. In February 2010 Proteologics signed a collaboration agreement with GlaxoSmithKline LLC (GSK). Under the terms of the collaboration agreement GSK and Proteologics will collaborate on six drug discovery projects. In March 2010 Proteologics completed an Initial Public Offering on the Tel-Aviv Stock Exchange. Proteologics currently has seven active drug discovery programs funded through equity funding and collaborations with strategic partners. Based on the terms of the GSK collaboration, in 2010 the number of active drug discovery programs are expected to increase to ten. The company is currently involved in identifying novel drugs to provide more effective treatment against metastatic cancers and in the discovery of therapeutic agents to interfere at several specific ubiquitin pathways relevant to a number of cancer tumor types.

 

.